Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x

MEDEXUS Aktie

>MEDEXUS Performance
1 Woche: 0%
1 Monat: -3,7%
3 Monate: +16,9%
6 Monate: -21,1%
1 Jahr: +42,9%
laufendes Jahr: -14,3%
>MEDEXUS Aktie
Name:  MEDEXUS PHARMACEUTIC.
Land:  Kanada
Sektor:  Gesundheit
ISIN/ Wkn:  CA58410Q2036 / A2PA3U
Symbol/ Ticker:  P731 (Frankfurt)
Kürzel:  FRA:P731, ETR:P731, P731:GR
Index:  -
Webseite:  https://www.medexus.com/
Marktkapitalisierung:  59.92 Mio. EUR
Umsatz:  94.77 Mio. EUR
EBITDA:  18.13 Mio. EUR
Gewinn je Aktie:  0.112 EUR
Schulden:  34.53 Mio. EUR
Liquide Mittel:  7.3 Mio. EUR
Umsatz-/ Gewinnwachstum:  19% / -
KGV/ KGV lG:  13.61 / 13.93
KUV/ KBV/ PEG:  0.46 / 1.99 / -
Gewinnm./ Eigenkapitalr.:  3.25% / 11.37%
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Insiderhandel:  -
Suchwörter:  MEDEXUS
Letzte Datenerhebung:  06.07.25
>MEDEXUS Eigentümer
Aktien: 32.26 Mio. St.
f.h. Aktien: 29.87 Mio. St.
Insider Eigner: 7.03%
Instit. Eigner: 3.19%
Leerverk. Aktien: -
>MEDEXUS Peer Group

 
26.06.25 - 00:30
 Medexus Pharmaceuticals Inc.: Medexus Announces Strong Fiscal Year 2025 Results, Including Initial Results from Launch of GRAFAPEX (treosulfan) for Injection in the United States (Newsfile)
 
Fiscal year 2025 revenue of $108.3 million, record net income of $2.2 million, operating income of $8.2 million, and record Adjusted EBITDA* of $20.2 millionUS commercial launch of GRAFAPEX execut......
17.06.25 - 23:06
 Medexus Pharmaceuticals Inc.: Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2025 Conference Call (Newsfile)
 
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 17, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, Ju......
17.04.25 - 13:06
 Medexus Pharmaceuticals Inc.: Medexus Successfully Completes Agreement for Public Reimbursement of Trecondyv (treosulfan for injection) in Quebec, Canada (Newsfile)
 
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 17, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) recently completed a listing agreement with the provincial government ......
07.04.25 - 13:12
 Medexus Pharmaceuticals Inc.: Medexus Provides Update on Progress of Commercialization of GRAFAPEX (treosulfan) for Injection (Newsfile)
 
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 7, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to provide a business update on the progress of the commerci......
14.03.25 - 12:06
 Medexus Pharmaceuticals Inc.: Medexus Completes Agreement to Return US Commercialization Rights for Gleolan to NX Development Corp. (Newsfile)
 
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - March 14, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) recently completed an agreement with NX Development Corp., the licenso......
24.02.25 - 13:06
 Medexus Pharmaceuticals Inc.: Medexus Announces Commercial Availability of GRAFAPEX (treosulfan) for Injection (Newsfile)
 
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 24, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that GRAFAPEX (treosulfan) for Injection is ......
06.02.25 - 15:54
 Medexus targets $100M annual revenue for GRAFAPEX within 5 years post-launch (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
05.02.25 - 23:48
 Medexus Pharmaceuticals Inc.: Medexus Announces Strong Fiscal Q3 2025 Results, Well-Positioned to Launch GRAFAPEX (treosulfan) for Injection in the United States (Newsfile)
 
Fiscal Q3 2025 revenue of $30.0 million, net income of $0.7 million, operating income of $3.8 million, and Adjusted EBITDA* of $5.8 millionManagement to host conference call at 8:00 AM Eastern tim......
05.02.25 - 23:42
 Medexus Pharmaceuticals reports Q3 results (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
04.02.25 - 13:06
 Medexus Pharmaceuticals Inc.: Medexus and Ontario′s Provincial Health Services Successfully Complete Agreements for Public Reimbursement of Trecondyv (treosulfan for injection) in Ontario, Canada (Newsfile)
 
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 4, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) recently completed listing agreements with Ontario's Ministry of Hea......
31.01.25 - 23:42
 Medexus Pharmaceuticals Inc.: Medexus Schedules Third Fiscal Quarter 2025 Conference Call (Newsfile)
 
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 31, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday,......
31.01.25 - 14:54
 Medexus Pharmaceuticals Inc.: Medexus Pharmaceuticals Announces Closing of $30 Million Overnight Marketed Public Offering of Common Shares (Newsfile)
 
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 31, 2025) - Medexus Pharmaceuticals Inc. (TSX: MDP) ("Medexus" or the "Company"), is pleased to announce the closing of its previo......
28.01.25 - 16:18
 XFRA : P731: Wiederaufnahme/Resumption (XETRA)
 
FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN MEDEXUS PHARMACEUTIC. P731 CA58410Q2036 AB/FROM ONWARDS 28.01.2025 16:10 CET...
28.01.25 - 15:36
 Medexus Pharmaceuticals Announces Pricing of $30 Million Overnight Marketed Public Offering of Common Shares (GlobeNewswire EN)
 
The Base Shelf Prospectus is accessible, and the Prospectus Supplement will be accessible within two business days, through SEDAR+...
28.01.25 - 08:01
 XFRA : P731: Aussetzung/Suspension (XETRA)
 
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL MEDEXUS PHARMACEUTIC. P731 CA58410Q2036 BAW/UFN...
28.01.25 - 07:51
 XFRA : INSTRUMENT_SUSPENSION - CA58410Q2036 (XETRA)
 
Instrument ID [2513] (P731 - CA58410Q2036) suspended...
27.01.25 - 22:21
 Medexus Pharmaceuticals announces overnight marketed public offering of common shares (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
22.01.25 - 17:06
 Medexus Pharmaceuticals Inc.: Medexus Announces FDA Approval of GRAFAPEX (treosulfan) for Injection and Provides Business Update (Newsfile)
 
Medexus will target a commercial launch in 1H CY2025; potential for annual product-level revenue to exceed US$100 million within five years after commercial launchToronto, Ontario and Chicago, Ill......
15.01.25 - 13:06
 Medexus Pharmaceuticals Inc.: Medexus and British Columbia′s Provincial Health Services Authority (PHSA) Successfully Complete Agreement for Public Reimbursement of Trecondyv (treosulfan for injection) in British Columbia, Canada (Newsfile)
 
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 15, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) recently completed a listing agreement with British Columbia's Provi......
02.12.24 - 13:06
 Medexus Pharmaceuticals Inc.: Medexus and medac Conclude Negotiations to Amend US Treosulfan Agreement, Setting Regulatory Milestone Amounts and Payment Schedule (Newsfile)
 
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - December 2, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that the company recently entered into a four......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Männer sind wie Luft, zwar versaut, aber unentbehrlich. - Michelle Pfeiffer
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!